You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Amyloid Beta Oligomer Induction of Alzheimer's Disease in Nonhuman Primates
SBC: Virscio Inc Topic: 100PROJECT SUMMARY Patients with Alzheimerandapos s diseaseADsuffer a progressive loss of memory and cognitive abilityand eventual loss of basic bodily functions and deathCurrentlyof Americans overhave AD and its incidence and toll on the healthcare system continues to rise with significant societal impactThere are no treatments for AD to prevent its inexorable courseand a principal obstacle to devel ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
System for providing an interface for interacting with an animal
SBC: NEUROTARGETING SYSTEMS Topic: ODABSTRACT A large number of studies require sampling biological signals stimulating the brain or infusing test substances in freely moving mice Although several forms of tethers are currently available for this purpose these devices restrain the mice s activity to some degree The animal s mobility is usually reduced even more when several connections are needed with the mouse i e electroenc ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia
SBC: Applied BioMath, LLC Topic: NIAProject Summary Abstract In there were an estimated million Americans living with Alzheimerandapos s Disease AD at an annual healthcare cost of $ billion Alzheimer s Association AD is characterized by accumulation of insoluble forms of amyloid A in brain interstitium and aggregation of the microtubule protein tau in neurofibrillary tangles in neurons The development of ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
New BDNF Nanoparticles for Early Treatment of Alzheimer s Disease
SBC: ExQor Technologies Inc Topic: NIAAlzheimerandapos s Disease AD represents a major chronic health problem in the US and abroad MRI studies of AD demonstrated a decrease in the size of the hippocampus and other brain structures associated with learning and memory Toxic proteins like A and tau accumulate in these brain regions and MRS and PET imaging studies consistently showed metabolic deficits and oxidative stress in brai ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive urinary monitoring of NASH by activity based nanosensors
SBC: Glympse Bio, Inc. Topic: 300Project Summary Abstract Nonalcoholic steatohepatitis NASH is dubbed the stealth epidemic and in the U S alone percent of the million people who are estimated to have NASH will progress and develop life threatening conditions including fibrosis cirrhosis hepatocellular carcinoma and liver failure By the year NASH is projected to be the leading indication for liver transplanta ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of TP for the Induction and Maintenance of Remission in Ulcerative Colitis Patients
SBC: Thetis Pharmaceuticals LLC Topic: 300ABSTRACT Thetis plans to investigate TP an innovative and potential first in class therapeutic agent as an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitis UC patients While the precise etiology of UC is unknown it is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
NNCI Synapse Development of a Mobile Application to Disseminate Neuroscience Training to Medical Professionals
SBC: C4 Innovations, LLC Topic: 102PROJECT SUMMARY ABSTRACT While biological models of mental illness once emphasized chemical imbalances modern perspectives increasingly incorporate a more nuanced understanding of genetics and epigenetics neurotransmitters and neuroplasticity and the functional dynamics of neural circuits Yet despite extraordinary advances in neuroscience that have dramatically enhanced our understanding ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
SBC: NAPROGENIX, INC. Topic: 150Abstract Alcohol dependence affects at leastof the US populationwith a financial cost in excess of $BnPrevention of relapse in patients attempting to reduce alcohol consumption is a major therapeutic targetbut current treatments are ineffectiveand there is an urgent need for new medicationsMajor factors in causing relapse include the protracted symptoms of withdrawal from alcoholwhich are relieved ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Cost efficient optical guidance for spinal fusion using existing radiographic equipment and augmented reality display
SBC: OnPoint Spine, Inc. Topic: NIBIBABSTRACT The technology that will be developed in this NIH SBIR Phase I and later Phase II proposal will provide novel systems for optical guidance of spinal surgery that will not use any of the expensive components currently used for surgical navigation intra operative CT or O arm imaging or robotics Instead the technology will leverage innovative new hardware such as optical head mounted d ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel D Printed Architectures for Oral Long acting Drug Delivery Systems
SBC: Lyndra Therapeutics, Inc. Topic: NIBIBNovel D Printed Architectures for Oral Long Acting Drug Delivery Systems Project Summary Long acting oral LAO dosage forms may offer significant benefits for managing chronic medical conditions requiring long term and intensive medication regimens particularly those in which observed therapy would be practical and advantageous such as psychiatric disorders Poor patient adherence and persist ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health